CAL
KNTE

Capital Advisors Ltd’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Capital Advisors Ltd’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-197
Closed – – 1537
2023
Q3 		$0 Buy
+197
New +$473 ﹤0.01% 1525

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Advisors Ltd's KNTE Position: Q4 2023 in Review

Capital Advisors Ltd sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 197 shares.

Capital Advisors Ltd first reported a position in KNTE in Q3 2023 and held it in 1 quarter. The position peaked at $0 in Q3 2023. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

  • Capital Advisors Ltd reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 197 Kinnate Biopharma Inc. Common Stock shares in Q4 2023.
  • Capital Advisors Ltd first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Capital Advisors Ltd's Kinnate Biopharma Inc. Common Stock position peaked at $0 in Q3 2023.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on Capital Advisors Ltd's 13F filing for Q4 2023, filed 2 Feb 2024.